



catching the unseen[®]


Transforming Lung Cancer Screening

Strategic Updates on eyonis[®] LCS

FREDRIK BRAG, CEO AND FOUNDER
COMPANY WEBCAST - FEBRUARY 26, 2026



Median Technologies is a publicly
listed company on Euronext Growth



IMPORTANT NOTICE – YOU MUST READ THE FOLLOWING BEFORE CONTINUING

This presentation contains forward-looking statements. These statements are not historical facts. They include projections and estimates as well as the assumptions on which these are based, statements concerning projects, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, or future performance.

These forward-looking statements can often be identified by the words "expects," "anticipates," "believes," "intends," "estimates" or "plans" and any other similar expressions. Although Median's management believes that these forward-looking statements are reasonable, investors are cautioned that forward-looking statements are subject to numerous risks and uncertainties, many of which are difficult to predict and generally beyond the control of Median Technologies, that could cause actual results and events to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.


All forward-looking statements in this presentation are based on information available to Median Technologies as of the date of the presentation. Median Technologies does not undertake to update any forward-looking information or statements, subject to applicable regulations, in particular Articles 223-1 et seq. of the General Regulation of the French Autorité des Marchés Financiers.


eyonis® LCS has received FDA 510(k) clearance for commercialization across the U.S. CE marking is pending; eyonis® LCS is not yet available in Europe.

You can submit your questions during the webcast

Submit questions for the Q&A

Type your questions in the chat box by selecting the questions icon located on the right side of your screen





Providing Invaluable Clinical Insights Where Others Only See Images

Leveraging Proprietary AI, Computer Vision, and Signal Processing Technologies to Develop Imaging Tests and Services for Unmet Needs in Oncology

Proven & experienced management team



Fredrik Brag

Chief Executive Officer, Founder,
Board Member



Oran Muduroglu

President of Median eyonis Inc.,
Executive Chairman of the Board



Jean-Christophe Montigny

Chief Financial Officer



Thomas Bonnefont

Chief Operating Officer &
Chief Commercial Officer of Median eyonis



Nicolas Dano

Chief Operating Officer &
Chief Commercial Officer of Median iCRO

EXTENSIVE PRIOR EXPERIENCE



**HealthCenter
/ Focus Imaging**



BOARD OF DIRECTORS



Fredrik Brag



Tim Haines



Kapil Dhingra



Oern Stuge



Ben McDonald



Didric Cederholm



iCRO

Continued Business Momentum & Improved Financial Profile

- Achieved record backlog – driven by U.S. demand: **€76.6M**
- 2025 revenue of **€23.5M**
- Cash flow positive
- Expanded footprint with top-tier pharmas



High Commercial Launch Readiness in Lung Cancer

- Achieved FDA 510(k) clearance & filed CE marking submission
- Appointed Oran Muduroglu as President of Median eyonis Inc. to lead the U.S. launch and scale-up, building on strong foundation of preparation
- Signed non-exclusive distribution agreement with Tempus
- Expanded KOL network across radiology, pulmonology & thoracic oncology

Summary Financials

- Company completed up to **€61.4M** refinancing in summer 2025 to significantly strengthen financial position.
- Cash position at **€18.2M** as of Dec. 31, 2025, current runway extended to **Q4:2026**
- As of Feb. 16, 2025:
 - Already exercised: **1.66M** warrants (eq. **€5.9M**)
 - Potential upside to cash position from 12.8M warrants: **€45.8M** in additional proceeds upon full exercise

eyonis[®]: proprietary pan-cancer suite of early diagnostic tests




eyonis[®] is Median's AI-powered Software as Medical Devices (SaMDs) portfolio:

- Enabling earlier and more accurate cancer diagnosis from medical images,
- Helping clinicians deliver better outcomes while reducing unnecessary procedures and lowering healthcare costs.

eyonis[®] first commercial opportunity in Lung Cancer Screening with eyonis[®] LCS:

- Designed and indicated for lung cancer screening using Low Dose Computed Tomography (LDCT, gold standard),
- Cleared by the FDA on Feb 6, 2026,
- Commercially available across the U.S. market now,
- CE mark expected in Q2 2026 for commercialization across Europe.



Why eyonis[®] starts with the Lung Cancer Screening market?



#1

**Cancer Killer
Worldwide⁽¹⁾**

18.6%

**of all lung cancer patients
survive 5 years⁽²⁾**

14.5M

U.S. eligible population⁽³⁾

19%

**Of All cancer Deaths
1.8 m deaths globally⁽¹⁾**

80%

**of patients diagnosed at an
early stage via LDCT
screening survive 20 years⁽²⁾**

\$10B

**U.S. Total Addressable
Market⁽⁴⁾**

[1] Cancer Tomorrow, IARC, Global Cancer Observatory 2020 - WHO

[2] Mountsinai - [Lung Cancer Screening Dramatically Increases Long-term Survival Rate](#)

[3] USPSTF – U.S. Preventive Services Task Force 2021

[4] Based on a \$650 per procedure reimbursement opportunity

Lung cancer screening - landmark studies:

NLST: *US based National Lung Screening Trial (53,454 participants, 2002-2004)*

NELSON: *Dutch-Belgian Randomized Lung Cancer Screening Trial (15,792 participants, 2004-2012)*

I-ELCAP: *International Early Lung Cancer Action Program (87,000 patients, 1992-2006)*



eyonis[®] LCS

A uniquely differentiated Software as a Medical Device for Lung Cancer Screening (LCS) programs



eyonis[®] LCS is uniquely differentiated and positioned

The Historical Diagnostic Paradigm for LCS is Inefficient

- X No end-to-end solutions to support radiologists
- X LCS is done by radiologist alone or aided by CADe
- X No CADx device currently approved in the U.S. for LCS indication

eyonis[®] LCS


- ✓ Only end-to-end solution for detection & characterization targeting LCS procedures
- ✓ Enhancing screening accuracy and efficiency



eyonis[®] LCS enables scaling up lung cancer screening



eyonis[®] LCS Workflow



- Easy-to-use
- Optimizes radiologist's time
- Increases workflow standardization
- No manual intervention
- Greater accuracy & efficiency

eyonis[®] LCS has demonstrated strong performance to support nationwide LCS at scale



Manufacturer Values (MV)

Performed to determine eyonis[®] LCS performance

Evaluated on a U.S. (NLST) cohort of 2,163 cases (136 cancers/2,027 benign) (66.18% stage I cancers)

Negative Predictive Value (NPV) 99.9%

	Sensitivity TP-Positive cases detected (malignant)	Specificity TN-Negative cases detected (benign)
Radiologist	80.3%*	76.4%*
eyonis[®] LCS Probably Benign Suspicious Very suspicious	93.3%	92.4%
	-66% FN	-68% FP

*2021 American Medical Association - Cochrane Library. Jonas DE, Reuland DS, Reddy SM, et al. Screening for lung cancer with low-dose computed tomography.



- Significantly reduces false positives and false negatives (missed cancers)
- Reduces unnecessary invasive diagnostic procedures
- Enables high-confidence rule-out (screening default) for annual follow-up
- Enables high-confidence efficient rule-in (recall) pathways for at-risk patients expedited diagnostic work-up
- Enables earlier lung cancer detection & characterization
- **Supports nationwide LCS at scale**



eyonis[®] LCS: commercial rollout in the U.S.

U.S. lung cancer screening momentum to propel eyonis[®] LCS adoption nationwide

- Large and expanding **lung cancer screening-eligible population**:
 - USPSTF guidelines recommend annual LDCT screening for adults 50–80 years with ≥20 pack-years smoking history,
 - Eligible population of **14.5 million people**,
 - High-risk population continues to expand due to smoking prevalence and aging demographics.
- **Established U.S. reimbursement pathway**, with the AI-powered software being reimbursable under Category III CPT codes 0721T and 0722T for quantitative CT tissue characterization, which are currently assigned to Medicare’s New Technology APC 1508.

\$10B

U.S. Total Addressable
Market

Existing reimbursement to support eyonis[®] LCS launch



Existing CPT III codes for tissue characterization under CT: 0721T & 0722T

CMS payment for 2 CPTIII codes assigned to New Tech APC 1508 - Level 8 (\$601 - \$700)

Total Medicare Hospital Payment is LDCT \$107 + eyonis[®] LCS \$650

CPT Code	CPT Description	Existing LDCT Images	Hospital Outpatient Payment
71271 APC 5522	Computed tomography, thorax, low dose for lung cancer screening , without contrast material(s)	LDCT	\$107
0721T APC 1508	Quantitative CT tissue characterization , including interpretation and report, obtained <i>without</i> concurrent CT examination of any structure contained in previously acquired diagnostic imaging Do not report 0721T in conjunction with 71271	YES	\$650
0722T APC 1508	0721T but with concurrent CT examination is code 0722T Use 0722T in conjunction with 71271	NO	\$650 + \$107

These two procedures provide an LDCT and tissue characterization & are billed on separate days

The tissue characterization is “added-on” to the LDCT & are billed on the same day

CMS CY 2023 Medicare Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System Final Rule

Strong platform clinical validation



Leveraging Top U.S. & EU-based Academic Clinical Sites Involved in Pivotal Studies

23 eyonis Conference Papers, Oral Presentations, and Publications since 2021



eyonis[®] LCS commercial launch and scale-up in the U.S.



Oran Muduroglu to lead U.S. Commercialization

 >3 decades of experience building, engineering, and scaling enterprise imaging and workflow platforms



 Experience leading complex national deployments requiring:

- Deep EMR and PACS interoperability
- Rigorous product development
- Disciplined enterprise sales
- Alignment with evolving reimbursement models

Key Pillars of the U.S. Commercial Strategy

Phased launch strategy for disciplined national, scalable expansion

- Detailed customer and payor mapping to prioritize regions with high lung-cancer screening volumes
- Targeting patients eligible for reimbursement
- Health-economics studies expected to initiate in 2026

Build-out of direct enterprise sales organization

- Expansion of robust U.S.-based commercial organization:
 - IT infrastructure and management
 - Application specialists
 - Sales/inside sales
 - U.S. marketing

Strategic non-exclusive distribution agreements

- Collaboration with Tempus announced on February 12, 2026, covering U.S. and EU.
- Plans to secure additional distribution collaborations with top-tier imaging, cloud technology and diagnostics partners

median + **"TEMPUS**

- Integration of eyonis[®] LCS into Tempus Pixel, an FDA-cleared, CE-marked AI-enabled solution that provides advanced analysis, tools, and automated reporting from radiology images
- Leverages Tempus' established position in oncology and AI-based precision medicine, and its strong network of healthcare providers, oncologists, and diagnostic centers
- Reinforces the clinical utility of the technology and facilitates adoption via an established enterprise workflow

Plans to broaden commercial adoption of eyonis[®] LCS by targeting additional non-exclusive distribution agreements with top-tier imaging, cloud technology & Dx partners



Growth strategy to expand eyonis[®] LCS and eyonis[®] reach

Well-defined growth strategy to expand eyonis[®] reach



Increase Presence in U.S.



- Sign additional non-exclusive distribution agreements
- Drive incremental clinical partnerships designed to enable broad awareness across LCS programs
- Initiate health-economics studies to work towards broader, long-term insurance coverage

Drive Traction in Europe



- Achieve eyonis LCS[®] CE marking (expected in Q2:2026)
- Leverage existing non-exclusive distribution agreement with Tempus to cover Europe
- Sign additional non-exclusive distribution agreements
- Focus on major countries (DE, FR, IT, PL) and quick wins

Expand Portfolio



- Leverage eyonis[®] CAdE/CADx AI expertise and clinical-regulatory know-how to expand into additional cancer indications
- Target: Incidental Pulmonary Nodules, HCC (liver cancer), pancreatic cancer, colon cancer, and prostate cancer



Q & A Session



ALMDT
EURONEXT
GROWTH

Our Core Values

Leading innovation with purpose

Combine the spirit of innovation with our passion and conviction to help cure cancer and other debilitating diseases.

Committing to quality in all we do

Be dedicated to quality in everything we do. Quality begins with us and we are committed to it.

Supporting our customers in achieving their goals

Listen to the needs of our customers and help make their goals our goals through our innovation, imaging expertise, superior services, and quality solutions.

Putting the patient first

There is a person at the other end of the images we analyze who is counting on us to do everything we can to help make them healthier.

Follow Us



 mediantechnologies.com

 linkedin.com/company/median-technologies

 youtube.com/user/MEDIANTechnologies
